BeOne Medicines Ltd. (ONC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$371.53

From 52W high−1.93%

Volume289127.00

Market cap$42.09B

P/E (TTM)4.9x

P/S (TTM)6.9x

Div yield—

Key dataOct 19, 2026

Open

$371.53

From 52W high

−1.93%

Volume

289127.00

Market cap

$42.09B

ValuationView details →

P/E (Fwd)

44.2x

EV/EBITDA

32.9x

P/E (TTM)

4.9x

RSI (14)

58.8

MomentumView details →

1D Return

+0.30%

YTD Return

+22.21%

SummaryUpdated Jun 1, 2026

BeiGene, Ltd. (NASDAQ:ONC) is a global biotechnology company founded in 2010 and headquartered in Camana Bay, Cayman Islands. The company has established itself as a leading oncology-focused pharmaceutical enterprise, specializing in the discovery, development, and commercialization of innovative cancer treatments. BeiGene went public in 2016 and has since grown into a significant player in the global oncology market, with operations spanning the United States, China, Europe, and other international markets. The company recently announced plans to redomicile to Switzerland and rebrand as BeOne Medicines, reflecting its evolution from a primarily China-focused biotech to a truly global pharmaceutical company.

Ask drillr about BeOne Medicines Ltd. →

ValuationView details →

P/E (Fwd)

44.2x

P/E (TTM)

4.9x

EV/EBITDA

32.9x

EV/Sales

6.2x

P/S (TTM)

6.9x

P/B (TTM)

8.1x

ProfitabilityView details →

Gross Margin

88.89%

Net Margin

10.70%

EBITDA Margin

18.92%

ROE (TTM)

12.67%

ROA (TTM)

7.15%

Asset Turnover

0.69x

GrowthView details →

Revenue YoY

+34.35%

EPS YoY

+4547.37%

FCF YoY

+653.85%

Revenue CAGR 3Y

+55.69%

EPS CAGR 3Y

+652.29%

EBITDA YoY

+884.89%

MomentumView details →

1D Return

+0.30%

YTD Return

+22.21%

1Y Return

+16.54%

RSI (14)

58.8

vs 50D SMA

+2.94%

vs 200D SMA

+15.00%

Capital & dividendView details →

Debt/Equity

0.22x

Current Ratio

3.40x

Quick Ratio

3.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.05

EPS Surprise

25.77%

Beats (12Q)

5/12

Next Q EPS Est

$1.61

Avg Surprise (4Q)

45.57%

Rev Surprise

4.95%

Financials snapshotView financials →

Revenue (TTM)

6.13B

Net Income (TTM)

655.71M

Op. CF (TTM)

1.69B

Next earningsNov 5, 2026 →

Latest newsMore news →

Hong Kong stocks closed higher on October 5, 2026, with the Hang Seng Index up 68 points (0.3%) at 24,040, the Hang Seng Tech Index up 25 points (0.6%) at 4,183, and the China Enterprises Index up 21 points (0.3%) at 8,051 on turnover of HK$98.102 billion.15d ago

Similar companies

Alibaba Health Information Technology Limited00241.HK 同仁堂600085.SH 益丰药房603939.SH Cellid, Co., Ltd.299660.KQ 康美药业600518.SH 西藏药业600211.SH Find similar companies →

Latest newsMore news →

BeOne Medicines completed negotiations with the pan-Canadian Pharmaceutical Alliance for TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.14d ago Hong Kong stocks closed higher on October 5, 2026, with the Hang Seng Index up 68 points (0.3%) at 24,040, the Hang Seng Tech Index up 25 points (0.6%) at 4,183, and the China Enterprises Index up 21 points (0.3%) at 8,051 on turnover of HK$98.102 billion.15d ago Hong Kong stocks opened slightly lower on Monday, with the Hang Seng Index down 8.88 points at 23,963.41, the Hang Seng Tech Index down 0.47% at 4,138.38 and the China Enterprises Index down 0.12% at 8,021.07.15d ago